Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease on September 17, 2026 Astellas Exophthalmos IGF1R protein, human Linsitinib NALF2 gene Phase 3 Series C financing Sling Therapeutics TED Thyroid associated opthalmopathies +
Sling raises $123M to push oral thyroid-eye-disease drug into Phase 3 on September 16, 2026 Forbion IGF1R protein, human Linsitinib NALF2 gene ORBIT trial Phase 3 Series C Sling Therapeutics Tepezza Thyroid associated opthalmopathies +
Zealand's royalty deal on August 14, 2026 Clinical Trials IGF-1R inhibitor Khartis Therapeutics NALF2 gene Oral Medicine Pharma Polycythemia royalty rusfertide PTG-300 Takeda Protagonist Therapeutics Thyroid associated opthalmopathies Vera Zealand +
Viridian's Lumvoa Gains FDA Nod for Thyroid Eye Disease, Setting Up Clash With Amgen's Tepezza on July 05, 2026 Amgen Tepezza active chronic thyroid eye disease Lumvoa FDA NALF2 gene subcutaneous elegrobart Thrive THRIVE-2 trials Viridian +
Immunovant's Batoclimab FcRn Inhibitor Fails Phase 3 Trials in Thyroid Eye Disease on April 02, 2026 Batoclimab FCGRT gene Immunovant NALF2 gene Thyroid associated opthalmopathies +